Biosimilars have provided for innovators and applic development and progress trials, regulatory and econ for Bioequivalence studies Testing and IVIVC. Biosimilars-2012 is a rem International mix of large an universities and Pharmacolo conference a perfect platform and academia and evaluate e Conference Highlights: 1. Biosimilars Path 2. EU mAb Guideli 3. Skill Set for Bios 4. Biosimilars Ther 5. Clinical Issues 6. Reference Stand 7. Guidelines for M 8. Bioequivalence T 9. In vitro & In vivo 10. Biowaivers 11. Pharmaceutics Important Dates: Avail the early bird discounts a Abstract Submission closes o Registration closes on: July 29 INTERNATIONAL CONFERE EXHIBITION ON BIOWAIVERS & BIOSIM SEPTEMBER 10-12, 2 HILTON SAN ANTONIO A TEXAS, USA many challenges and opportunities in e cants. Biosimilars-2012 is designed to s of research in the areas of drug disc nomic considerations towards Biosimila s, BCS Biowaiver Studies, Dosage form markable event which brings together nd medium Pharmaceutical, Biotech comp ogical and Biomedical research institution m to share experience, foster collaborations emerging technologies across the globe. hways ines similars development rapeutics dards Marketing Testing o Correlations and register on/before April 23, 2012. on: July 20, 2012 9, 2012 ENCE AND MILARS 2012 AIRPORT equal measure o discuss the covery, clinical ars and waiver ms, Dissolution a unique and panies, leading ns making the across industry
3
Embed
INTERNATIONAL CONFERENCE AND TEXAS warmly invite you to attend and submit your abstract to and Exhibition on Biowaivers and Biosimilars. Biosimilars-2012 is comprised of 11 tracks
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Biosimilars have provided many challenges and opportunities in equal measure for innovators and applicants. Biosimilarsdevelopment and progress of research in the areas of drug discovery, clinical trials, regulatory and economic considerations towards Biosimilars and for Bioequivalence studies, BCS Biowaiver Studies, Dosage forms, Dissolution Testing and IVIVC.
Biosimilars-2012 is a remarkable event which brings together a unique and
International mix of large and medium Pharm
universities and Pharmacological
conference a perfect platform to sha
and academia and evaluate emerging technologies across the globe.
Conference Highlights:
1. Biosimilars Pathways
2. EU mAb Guidelines
3. Skill Set for Biosimilars development
4. Biosimilars Therapeutics
5. Clinical Issues
6. Reference Standards
7. Guidelines for Marketing
8. Bioequivalence Testing
9. In vitro & In vivo
10. Biowaivers
11. Pharmaceutics
Important Dates:
Avail the early bird discounts and register on/before
Abstract Submission closes on:
Registration closes on: July 29,
INTERNATIONAL CONFERENCE
EXHIBITION ON
BIOWAIVERS & BIOSIMILARS
SEPTEMBER 10-12, 2012
HILTON SAN ANTONIO AIRPORT
TEXAS, USA
Biosimilars have provided many challenges and opportunities in equal measure for innovators and applicants. Biosimilars-2012 is designed to discuss the development and progress of research in the areas of drug discovery, clinical
nomic considerations towards Biosimilars and for Bioequivalence studies, BCS Biowaiver Studies, Dosage forms, Dissolution
is a remarkable event which brings together a unique and
International mix of large and medium Pharmaceutical, Biotech companies,
universities and Pharmacological and Biomedical research institutions making the
conference a perfect platform to share experience, foster collaborations across industry
and academia and evaluate emerging technologies across the globe.
Biosimilars Pathways
EU mAb Guidelines
Skill Set for Biosimilars development
Biosimilars Therapeutics
Reference Standards
Guidelines for Marketing
Bioequivalence Testing
n vivo Correlations
Avail the early bird discounts and register on/before April 23, 2012.
closes on: July 20, 2012
29, 2012
INTERNATIONAL CONFERENCE AND
ON
BIOSIMILARS
2012
O AIRPORT
Biosimilars have provided many challenges and opportunities in equal measure 2012 is designed to discuss the
development and progress of research in the areas of drug discovery, clinical nomic considerations towards Biosimilars and waiver
for Bioequivalence studies, BCS Biowaiver Studies, Dosage forms, Dissolution
is a remarkable event which brings together a unique and
Biotech companies, leading
research institutions making the
re experience, foster collaborations across industry
We warmly invite you to attend and submit your abstract to
and Exhibition on Biowaivers and Biosimilars.
Biosimilars-2012 is comprised of 11 tracks and
comprehensive sessions that address current issues related to Biowaivers and
Biosimilars.
Who should attend?
Legal Affairs, Principal Scientists, Chief Scientific Officers, R